REMUS — Remus Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Remus Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	119	184	247	450	2,125
Cost of Revenue
Gross Profit	48.8	69.2	124	236	482
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	116	178	208	350	1,856
Operating Profit	2.87	5.87	39.2	101	269
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10.9	13.6	45.5	114	318
Provision for Income Taxes
Net Income After Taxes	8.12	10.3	33.9	85	260
Minority Interest
Net Income Before Extraordinary Items
Net Income	8.12	10.3	33.9	85	215
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8.12	10.3	33.9	85	215
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.38	1.74	5.75	20.8	35.8
Dividends per Share